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ABSTRACT
Testing for anti-hepatitis C virus (HCV) antibod-
ies in pools may reduce blood screening costs,
making this approach affordable for developing
countries, provided that the dilution of infected
blood does not signiﬁcantly increase the number
of undetectable viral particles, especially in sero-
converters. This study assessed the delay in
detection of HCV antibodies in ﬁve HCV
seroconversion panels, tested in pools of 6–48
samples, and estimated the risk of transfusion-
transmitted HCV caused by pooling. The delay in
detection of positive samples was 5–12 days for
pools of all sizes, adding 7% to the risk of HCV
transmission that occurs when blood donors’
samples are tested individually.
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A high general prevalence of hepatitis C virus
(HCV) in developing countries, particularly
among blood donor populations [1–3], is exacer-
bated by an inability to afford compulsory screen-
ing of blood donations. Only 15 of 24 Caribbean
countries reported universal screening for HCV in
their blood banks in 2003 [4], which is similar to
the situation in Thailand [5] and other developing
regions [6–8]. As a result, the risk of transfusion-
transmitted HCV infection has been estimated as
one per 12 471 donations in Caribbean countries
[4]. Screening in pools, in which several samples
are tested simultaneously, could be a potential
solution for resource-poor countries if performed
with highly sensitive anti-HCV immunoassays.
Screening in pools of 5–10 samples has been
found to be beneﬁcial, with practically no effect
on the accuracy of testing [9–12]. However, these
studies included tests of veriﬁed positive sam-
ples. Donations during seroconversion are expec-
ted to have a low virus particle count, which
could become undetectable in pools. Pooling
therefore has the potential of broadening the
window period for detection of HCV antibodies.
The aim of the present study was to estimate the
delay in detection of anti-HCV-positive samples
caused by testing in pools during the seroconver-
sion period as compared to individual testing.
Five seroconversion panels were used, identi-
ﬁed as PHV910, PHV916, PHV908, PHV915 and
PHM920 (Boston Biomedica Inc., West Bridge-
water, MA, USA). The average length of the
panels was 28 days, with blood samples taken
approximately once every 3.5 days. A mixture of
24 anti-HCV-negative samples, obtained from the
routine individual screens of Magen David Adom
National Blood Services (Israel), was used for
dilution. The use of this mixture was intended to
enlarge the possible background variance. Indi-
vidual samples from every blood sample of each
panel were pooled manually with the mixture of
24 HCV-negative samples in pool sizes of six, 12,
16, 24, 32 and 48 samples (i.e., a pool of six
samples included one part from a seroconversion
sample and ﬁve parts of the anti-HCV-negative
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mixture). Anti-HCV testing was performed in
duplicate, using the Axsym and ⁄ or IMx assays
(Abbott Laboratories, Abbott Park, IL, USA),
unless an insufﬁcient volume of the panel sample
did not allow repeated testing. The results for the
duplicate tests are presented as an average of the
two readings. Results with sample ⁄ cut-off values
‡0.8 were considered to be positive.
The delay in detection of HCV in pools was
calculated as the difference between the time of
initial detection in any pool and the time of
detection in an individual test. Estimates were
statistically generalised over the panels by log-
linear robust regression analysis [13]. The esti-
mate of delay established for all panels was
converted into the estimated additional risk of
tranfusion-transmitted infection caused by the
artiﬁcially prolonged window period. This calcu-
lation was based on the incidence risk ⁄window
period model [14], and assumed a baseline esti-
mated risk of 1 ⁄ 276 000 for transfusion-transmit-
ted HCV [7], and an average window period of
70 days for the detection of anti-HCV antibodies
[15].
The initial results for each panel are summa-
rised in Table 1. The delay in detecting the ﬁrst
positive sample increased with the pool size.
Testing in pools of six and 12 samples is unlikely
to cause a signiﬁcant delay, i.e., only an additional
3 – 4 days, with the exception of samples with low
individual readings, which had maximum delays
of 12 and 14 days using the Axsym and IMx
assays, respectively. There was a slight difference
in the results of individual tests with the IMx and
Axsym assays.
The regression analysis (Fig. 1) incorporated all
the data obtained for the HCV seroconversion
panels. The window period for testing in pools of
six and 12 is c. 5 days longer than that for
individual tests. This delay corresponds to 7%
of the ‘customary’ 70-day window period [15],
which increases the risk of transfusion-transmit-
ted HCV by 7%. Thus, the risk of transfusion-
transmitted HCV following testing in pools of
6–12 samples is expected to be <1 ⁄ 257 944 (after
adding 7% to the risk for individual tests
(1 ⁄ 276 000)).
These results are consistent with previous
studies which have reported that pooling for
anti-HCV testing is accurate and efﬁcient when
performed in pools of 5–10 samples (close to 6–12)
Table 1. Difference (in days) in detection of the ﬁrst hepatitis C virus (HCV)-positive sample in seroconversion panels,
tested individually and in pools
IMx assay
Average readings of S ⁄CO for the ﬁrst positive individual sample Axsym assay
Panel catalogue no. 916 910 915 920 908 916 910 915 920 908
S ⁄CO of the ﬁrst
positive blood
sample in
individual testsa
4.63 3.73 2.83 1.18 0.86 1.78 3.29 2.09 1.62 1.11
Days to the ﬁrst
positive individual
test result (days of
follow-up in the panel)
13 (28) 0 (15) 14 (14) 13 (35) 13 (48) 16 (28) 8 (15) 14 (14) 13 (35) 11 (48)
Pool size Delay in detection of positive sample in pools (in days)b
6 4 0 0 3 12 3 0 0 3 14
12 4 0 0 7 12 3 3 0 3 8
16 9 0 >0 13 12 3 3 0 7 14
24 9 0 >0 13 12 7 7 >0 13 14
32 >9 0 >0 15 14 12 7 >0 13 16
48 9 0 >0 15 19 7 >7 >0 13 14
aThe threshold for a positive serological status is 0.8.
bDelays listed as ‘>’ denote cases in which no positive sample was detected and the delay is more than the stated number of days.
S ⁄CO, sample ⁄ cut-off value.
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Fig. 1. Estimated delay in detection of anti-hepatitis C
virus antibodies caused by testing in pools of different
sizes as compared with individual tests.
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using the seroconversion window period [9–11].
Returning to the example of Caribbean countries
given above, the WHO report on blood banking in
21 Caribbean countries (http://www.paho.org/
English/HSP/HSE/HSE06/bloodbanks-caribb2002.
pdf) revealed that the total number of blood
donations screened for anti-HCV antibodies dur-
ing 2002 in these countries was 25 483, and that
the average prevalence of HCV infection among
those countries was 0.23%. Approximately 8900
donations were not screened for anti-HCV anti-
bodies, suggesting that 21 infected units may have
been transfused (0.23% · 8900). Taking into con-
sideration the fact that three different blood com-
ponents are produced from each whole blood unit
(packed red blood cells, plasma and platelet
and ⁄ or cryoprecipitate), 63 infections could have
been prevented by HCV screening. Estimating the
cost of testing as 3.5 Euros (US$ 5) per unit (http://
www.cdc.gov/mmwr/preview/mmwrhtml/rr5203a1.
htm), individual screening of 8900 donations
would cost 31 150 Euros (US$ 44 500), while
screening in pools of six could have saved
25 960 Euros (US$ 37 083). To make pooled
screening beneﬁcial for Caribbean countries, the
life-cost of an infected patient must exceed
440 Euros (US$ 588); however, the actual life-cost
of an HCV-infected patient to society is expected
to far exceed that amount.
Implementation of pooled screening in a blood
bank setting should be considered with regard to
the prevalence of the virus in the donor popula-
tion of each country, and the corresponding trade-
off with the size of a pool. The higher the
prevalence of the virus, the smaller the optimal
size of the pools. Based on the present results and
the consistency of experiments with routine blood
donations and seroconversion panels, screening
for anti-HCV antibodies in pools of six samples
can be recommended for countries in which
mandatory screening of all blood donations for
HCV cannot be afforded.
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